Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer

Oncology Letters

Volumn 6, Issue 6, 2013, Pages 1665-1672

  Tuomela, Johanna ^a,b   Sandholm, Jouko ^a,b   Kauppila, Joonas H ^c,d   Lehenkari, Petri ^c,d   Harris, Kevin W ^a,e   Selander, Katri S ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Chloroquine; Hypoxia; Toll like receptor 9; Triple negative breast cancer

Indexed keywords

CHLOROQUINE; COLLAGENASE 3; GELATINASE A; GELATINASE B; MESSENGER RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR PROMOTION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84886773849     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1602     Document Type: Article

References (25)

1. Elias AD: Triple-negative breast cancer: a short review. Am J Clin Oncol 33: 637-645, 2010.
2. Carotenuto P, Roma C, Rachiglio AM, Botti G, D'Alessio A and Normanno N: Triple negative breast cancer: from molecular portrait to therapeutic intervention. Crit Rev Eukaryot Gene Expr 20: 17-34, 2010.
3. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K and Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745, 2000.
4. Di JM, Pang J, Pu XY, Zhang Y, Liu XP, Fang YQ, Ruan XX and Gao X: Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells. Cancer Genet Cytogenet 192: 60-67, 2009.
5. Assaf A, Esteves H, Curnow SJ and Browning MJ: A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines. Cell Immunol 259: 90-99, 2009.
6. Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, et al: Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 6: 1534-1543, 2008.
7. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67: 774-781, 2007.
8. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW and Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4: 437-447, 2006.
9. Tuomela J, Sandholm J, Karihtala P, Ilvesaro J, Vuopala KS, Kauppila JH, Kauppila S, Chen D, Pressey C, Härkönen P, et al: Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat 135: 481-493, 2012.
10. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527, 2006.
11. Sandholm J, Kauppila JH, Pressey C, Tuomela J, Jukkola-Vuorinen A, Vaarala M, Johnson MR, Harris KW and Selander KS: Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells. Breast Cancer Res Treat 132: 411-419, 2012.
12. Chaudary N and Hill RP: Hypoxia and metastasis in breast cancer. Breast Dis 26: 55-64, 2006-2007.
13. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL and Quigley JP: Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274: 13066-13076, 1999.
14. Yeomans ND: Aspirin: old drug, new uses and challenges. J Gastroenterol Hepatol 26: 426-431, 2011.
15. Vazquez-Martin A, López-Bonetc E, Cufi S, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B and Menendez JA: Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat 14: 212-223, 2011.
16. Solomon VR, Hu C and Lee H: Design and synthesis of chloroquine analogs with anti-breast cancer property. Eur J Med Chem 45: 3916-3923, 2010.
17. Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, Huryk H, Mueller C, Adamo L, Deng J, et al: Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One 5: e10240, 2010.
18. Hu C, Raja Solomon V, Cano P and Lee H: A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells. Eur J Med Chem 45: 705-709, 2010.
19. Rahim R and Strobl JS: Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 20: 736-745, 2009.
20. Loehberg CR, Thompson T, Kastan MB, Maclean KH, Edwards DG, Kittrell FS, Medina D, Conneely OM and O'Malley BW: Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. Cancer Res 67: 12026-12033, 2007.
21. Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, Fabry B, Kalender WA, Koch T, Wachter DL, et al: Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001. Biochem Pharmacol 83: 480-488, 2012.
22. Jiang PD, Zhao YL, Deng XQ, Mao YQ, Shi W, Tang QQ, Li ZG, Zheng YZ, Yang SY and Wei YQ: Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer. Biomed Pharmacother 64: 609-614, 2010.
23. Yerlikaya A, Okur E and Ulukaya E: The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour Biol 33: 1385-1392, 2012.
24. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B and Jerala R: Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 186: 4794-4804, 2011.
25. Zhu X, Pan Y, Li Y, Jiang Y, Shang H, Gowda DC, Cui L and Cao Y: Targeting Toll-like receptors by chloroquine protects mice from experimental cerebral malaria. Int Immunopharmacol 13: 392-397, 2012.